{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:17:38Z","timestamp":1777907858566,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>Viloxazine hydrochloride is a member of a series of compounds which\nwas developed to explore the central nervous system activity of the aryloxypropanolamine\ntype of \u03b2-adreno-receptor antagonists [Mallion et al.,\n1972], Initial clinical trials have confirmed expectations that viloxazine\nwould have antidepressant activity [Bereen, 1973; Peet, 1973; Bayliss et al.,\n1974; Tsegos and Ekdawi, 1974; Pichot et al., 1975; Mahapatra, 1975].\nTo test the hypothesis that viloxazine has a therapeutic effect in\npatients suffering from endogenous depression, a 4-week double-blind standard\ncontrolled (amitriptyline) clinical trial was designed.<\/jats:p>","DOI":"10.1159\/000468584","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:44Z","timestamp":1502472044000},"page":"280-286","source":"Crossref","is-referenced-by-count":5,"title":["Viloxazine in the Treatment of Endogenous Depression"],"prefix":"10.1159","author":[{"given":"William M.","family":"Petrie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:49:57Z","timestamp":1777643397000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468584","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}